Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.5
4.8
Journals
Antibiotics
Special Issues
The Evidence Base for Treatment of Tickborne Infections
share announcement

The Evidence Base for Treatment of Tickborne Infections

A special issue of Antibiotics (ISSN 2079-6382).

Deadline for manuscript submissions: closed (30 April 2021) | Viewed by 15455

Special Issue Editors

Dr. John Lambert

E-Mail Website
Guest Editor
Department of Infectious Diseases, University College Dublin, Dublin, Ireland
Interests: infectious diseases; tickborne infections; congenital lyme and infections in pregnancy; travel and tropical medicine, blood borne infections (HBV, HCV)
Special Issues, Collections and Topics in MDPI journals
Dr. Brendan O Kelly

E-Mail Website
Guest Editor
Department of Infectious Diseases, University College Dublin, Dublin, Ireland
Interests: HIV and hepatitis C infection

Special Issue Information

Dear Colleagues,

There needs to be a review of the different tickborne infections in 'immunocompetent hosts' and a review of the clinical manifestations and treatment options. For example, babesia is only described as a problem with splenectomised patients, but there is a wide spectrum of disease in immunocompetent hosts. And the issue of treatment of these infections needs to be analysed and summarised. While a short course of antibiotic treatment may work for early diagnosed infections, sometimes patients need longer course treatment, just like for other infections. For example, early diagnosed Coxiella burnetti infection caught early requires only short course antibiotic treatment. However late diagnosed infection with Coxiella requires longer treatment. This Special Issue aims to review these issues, and look at special populations who are infected with tickborne infections: immunocompetent, immunosuppressed, and special issues that arise in pregnancy and children. We hope to publish a collection of excellent papers on this topic, some review articles and some original studies.

Dr. John Lambert
Dr. Brendan O Kelly
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Tickborne infections
  • Lyme disease
  • Co-infections
  • infections in pregnancy and children

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

17 pages, 227 KiB  
Article
“Repurposing” Disulfiram in the Treatment of Lyme Disease and Babesiosis: Retrospective Review of First 3 Years’ Experience in One Medical Practice
by Jiachen Gao, Zhaodi Gong, Dawn Montesano, Erica Glazer and Kenneth Liegner
Antibiotics 2020, 9(12), 868; https://doi.org/10.3390/antibiotics9120868 - 04 Dec 2020
Cited by 13 | Viewed by 9194
Abstract
A total of 71 patients with Lyme disease were identified for analysis in whom treatment with disulfiram was initiated between 15 March 2017 and 15 March 2020. Four patients were lost to follow-up, leaving 67 evaluable patients. Our retrospective review found patients to [...] Read more.
A total of 71 patients with Lyme disease were identified for analysis in whom treatment with disulfiram was initiated between 15 March 2017 and 15 March 2020. Four patients were lost to follow-up, leaving 67 evaluable patients. Our retrospective review found patients to fall into a “high-dose” group (≥4 mg/kg/day) and a “low-dose” group (<4 mg/kg/day). In total, 62 of 67 (92.5%) patients treated with disulfiram were able to endorse a net benefit of the treatment with regard to their symptoms. Moreover, 12 of 33 (36.4%) patients who completed one or two courses of “high-dose” therapy enjoyed an “enduring remission”, defined as remaining clinically well for ≥6 months without further anti-infective treatment. The most common adverse reactions from disulfiram treatment in the high-dose group were fatigue (66.7%), psychiatric symptoms (48.5%), peripheral neuropathy (27.3%), and mild to moderate elevation of liver enzymes (15.2%). We observed that although patients on high dose experienced a higher risk for adverse reactions than those on a low dose, high-dose patients were significantly more likely to achieve enduring remission. Full article
(This article belongs to the Special Issue The Evidence Base for Treatment of Tickborne Infections)

Other

Jump to: Research

9 pages, 242 KiB  
Perspective
Evidence-Based, Patient-Centered Treatment of Erythema Migrans in the United States
by Elizabeth L. Maloney
Antibiotics 2021, 10(7), 754; https://doi.org/10.3390/antibiotics10070754 - 22 Jun 2021
Cited by 3 | Viewed by 5210
Abstract
Lyme disease, often characterized as a readily treatable infection, can be a debilitating and expensive illness, especially when patients remain symptomatic following therapy for early disease. Identifying and promoting highly effective therapeutic interventions for US patients with erythema migrans (EM) rashes that return [...] Read more.
Lyme disease, often characterized as a readily treatable infection, can be a debilitating and expensive illness, especially when patients remain symptomatic following therapy for early disease. Identifying and promoting highly effective therapeutic interventions for US patients with erythema migrans (EM) rashes that return them to their pre-infection health status should be a priority. The recently released treatment recommendations by the Infectious Diseases Society of America/American Academy of Neurology/American College of Rheumatology (IDSA/AAN/ACR) for the treatment of US patients fall short of that goal. This paper reviews the US trial evidence regarding EM rashes, discusses the shortcomings of the IDSA/AAN/ACR recommendations in light of that evidence and offers evidence-based, patient-centered strategies for managing patients with erythema migrans lesions. Full article
(This article belongs to the Special Issue The Evidence Base for Treatment of Tickborne Infections)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop